Quarterly Report III 18/19

September 2018 – May 2019, Diamyd Medical AB (publ), Fiscal year 2018/201DIAGNODE-2 is fully recruited. Results are expected in Q3 2020Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B.Further information is available on https://www.diamyd.com Figures in parentheses relate to the corresponding period previous financial year. September 1, 2018 – May 31, 2019 ·  Net income: MSEK 1.3 (0.6), whereof third quarter MSEK 0.9 (0). The change refers to increased sales of GAD-protein for pre-clinical research. ·  Net result: MSEK -26.8 (-32.5), whereof